What if China gets the RI label rather than the MARINE label and Amarin loses the patent battle (in USA), in a race to being the world's #1 power, this instantly puts USA in a disadvantage, with CVD being the #1 killer and no ability to advertise Vascepa to the masses in the USA.
Here are Terra's comments on this topic:
Eddingpharm with updates re their MARINE-like P3 study in China. They also have completed their PK & ethnic comparisons. Potentially, if data acceptable, & MARINE-type shows results consistent w/US findings, may be allowed to use US REDUCE-IT results $AMRNhttps://t.co/zqa9gSKx4mpic.twitter.com/jAkBEiqhbp
Chris, reading your post made me think of something. Does Amarin have patents in Canada? Is there any concern or thought that generic V would be able to be sold there if it became available here?